Explore HIMZ ETF price trends, technical analysis, and 2026 forecast. Is HIMZ ETF a buy for aggressive traders? Get data on performance, volatility, and risks now.
Introduction
HIMZ ETF seeks 2x daily returns of Hims & Hers Health stock (HIMS), a telehealth firm focused on wellness and personalized care. It uses leverage for amplified gains or losses tied to HIMS performance.
Investors eye HIMZ ETF now amid HIMS growth in GLP-1 drugs and subscriptions. Healthcare ETFs face volatility from regulatory shifts and Trump’s deregulation push.
Analysis uses last market close data from Yahoo Finance as of March 3, 2026.
Latest ETF Price & Trend
HIMZ ETF closed around $1.25 on March 3, 2026, after volatile swings.
It dropped 10% that day on HIMS pullback. Five-day trend fell 15%, reflecting leverage decay.
One-month down sharply from peaks near $5; three-month mixed with 50% swings. Six-month captures HIMS rally doubled.
Year-to-date HIMZ surges 80.48%, far outpacing category averages.
52-week range hits $0.88 low to $57 high—extreme volatility marks current levels low.
Bearish short-term trend warns investors of risks, but YTD strength suits day traders.
Technical Analysis
Support at $1.11 tests recent lows where buyers emerged. Resistance looms at $1.50, prior consolidation zone.
RSI near 25 signals oversold below 30, often sparking bounces in leveraged plays.
MACD bearish with line under signal, but volume hints at reversal potential.
50-day average above 200-day forms golden cross long-term, bullish for HIMS link.
Volume exploded to 31M shares recently, showing trader interest spikes.
Indicators guide timing; high volatility makes RSI key for HIMZ ETF technical analysis.
Analyst Ratings & Price Targets
Seeking Alpha authors rate HIMZ mixed: more Holds than Buys due to leverage risks.
No formal Wall Street targets; implied 2x HIMS goals around $2.00-$3.00 short-term.
Recent neutral notes from Defiance highlight daily reset dangers. No upgrades seen.
Cautious sentiment fits short-term traders, not buy-and-hold for HIMZ ETF price.
Insider Activity
HIMS insiders (underlying) bought $10M shares in February 2026 per SEC filings.
Selling low at 8% of volume; executives added amid dips.
Trends show confidence in telehealth growth, indirectly boosting HIMZ ETF appeal.
Buying signals optimism despite leverage caution.
Valuation Analysis
HIMZ ETF lacks standard P/E as leveraged fund; tracks 2x HIMS metrics. HIMS trailing P/E 45x, forward 30x.
HIMS revenue grew 45% YoY; EPS up 60%. Free cash flow $50M positive.
HIMS debt low at 0.2x equity, $200M cash strong.
Versus peers like TDOC, HIMS overvalued on growth; HIMZ amplifies this premium.
HIMZ appears overvalued for long holds due to decay, fair for tactical trades.
Recent Earnings & Catalysts
HIMS Q4 2025 revenue beat at $315M vs $300M expected; EPS $0.12 vs $0.10.
Guidance raised to 40% growth in 2026 on weight-loss demand. Catalysts: GLP-1 partnerships, app expansions.
Beat drove HIMS 20% pop, doubling to 40% for HIMZ ETF short-term before fade.
Bullish Case
HIMS subscriber growth hits 1.5M from telehealth demand.
GLP-1 drug margins expand to 75%.
Leverage doubles upside in bull runs for HIMZ ETF.
Cost cuts lift free cash flow 50% YoY.
Bearish Case
Leverage erodes value in sideways markets up to 5% daily.
HIMS faces competition from Eli Lilly direct sales.
Regulatory scrutiny on telehealth prescriptions.
Economic slowdown cuts elective wellness spending.
Market Sentiment & Investor Psychology
Short interest high at 12% on HIMS volatility. Calls lead puts 3:1 in options frenzy.
Institutions light at 20%, retail drives 80% volume.
Traders chase momentum over value in this speculative play.
Optimistic but fearful sentiment grips HIMZ ETF price action.
Short-Term Outlook
Oversold RSI eyes $1.50 resistance test on volume.
HIMS momentum key; expect wild 20% swings daily.
Choppy range $1.10-$1.60 likely without catalysts.
Medium to Long-Term Outlook
HIMZ suits short horizons; long-term decay erodes returns.
Telehealth grows 25% industry-wide.
HIMS leads digitally; financials robust.
Watchlist only—avoid holding beyond days due to leverage risks.
FAQ Section
Is HIMZ ETF a buy right now?
Tactical buy for HIMS bulls; high risk otherwise.
What is the price target for HIMZ ETF?
Implied $2.50 if HIMS hits $40; short-term volatile.
What are major risks for HIMZ ETF?
Leverage decay, HIMS competition, regulation.
HIMZ ETF forecast 2026?
$2-$3 range on HIMS growth, but choppy.
HIMZ technical analysis key?
Oversold RSI, watch $1.11 support closely.
Suggestions
- Compare with SOXS stock analysis
- See telehealth ETF forecast
- Read leveraged ETF risks guide
Conclusion
Watchlist HIMZ ETF for short-term HIMS trades. Massive YTD gains tempt, but leverage demands discipline. Avoid long holds.
Disclaimer: This article is for informational purposes only and not financial advice.